Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous labetalol versus oral nifedipine for severe hypertensive disorders of pregnancy
PACTR202504557828315Phase 4Not yet recruiting
- Sponsor
- MBEREOBONG SATURDAY ETUK
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in maternal hypertension (HDP) comparing Intravenous labetalol arm with Oral nifedipine arm (2 arms). Primary endpoint: Efficacy of blood pressure control. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
labetalolnifedipine
03
Conditions
maternal hypertension (HDP)
Beyond the preview
Go deeper on PACTR202504557828315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202504557828315.